secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0000950170-25-090170
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics reports up to 86% LDL reduction with CTX310; delays CTX320 data to H1 2026
--------------------------------------------------------------------------------

- CTX310 Phase 1 shows up to 82% TG and 86% LDL reductions at 0.8 mg/kg with stable liver enzymes.
- CTX320 (LPA gene) Phase 1 data update expected in first half of 2026 due to strategic pause for Lp(a) landscape insights.
- CTX340 (AGT gene) for refractory hypertension advancing through IND/CTA-enabling studies.
- CTX310 trial enrolling HoFH, severe hypertriglyceridemia, HeFH, and mixed dyslipidemia patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025090170/0000950170-25-090170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025090170/crsp-20250626.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-090170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer